Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Hepatocellular 202Carcinoma, Renal Cell 68Liver Neoplasms 61Neoplasms 53Neoplasm Metastasis 34Leukemia, Myeloid, Acute 34Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 29Melanoma 24Kidney Neoplasms 21Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Recurrence 13Glioblastoma 13Thyroid Neoplasms 11Colorectal Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Carcinoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Cisplatin 253Radiotherapy 176Cetuximab 145pembrolizumab 120Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Cyclophosphamide 22Gefitinib 21Surveys and Questionnaires 20Standard of Care 20Surgical Procedures, Operative 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15130-nm albumin-bound paclitaxel 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × Sorafenib × Clear all
NCT00703638 2017-11-29

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
16 enrolled
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00199160 2015-05-20

Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Jules Bordet Institute

Phase 2 Completed
60 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡